Trial Profile
SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavi/r IN Race/Gender HIV+ Patients Randomized to Therapeutic Drug Monitoring or Standard of Care
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Tipranavir (Primary) ; Ritonavir
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms SPRING
- Sponsors Boehringer Ingelheim
- 08 Apr 2022 This trial has been completed in Spain (End Date: 20 Oct 2010), according to European Clinical Trials Database record.
- 27 Nov 2008 Actual patient number reported as 33 by ClinicalTrials.gov.
- 27 Nov 2008 Actual end date reported as October 2008 by Clinicaltrials.gov.